In the BioFINDER-2 cohort, the baseline distribution of insoluble tau aggregates assessed via tau-PET recapitulated the AD-typical deposition in the medial and lateral temporal lobes in the controls and non-demented participants, and into lateral and medial parietal and lateral occipital regions at symptomatic AD stages (Fig. 1a and Supplementary Fig. 1 for CU and MCI separately). This evidence concerns the gene MAPT and Alzheimer disease.